Japanese Society for Infection Prevention and Control-Online Journal

Full Text of PDF (321K)
Article in Japanese

Influence of Teicoplanin and Tazobactam/Piperacillin Combination Therapy on Renal Function

Shota MATSUYA and Shunsuke KAWAHATA
Kansai Rosai Hospital

In recent years, the use of vancomycin (VCM) in combination with tazobactam/piperacillin (TAZ/PIPC) has been reported to increase the incidence of acute kidney injury (AKI). However, reports on the use of teicoplanin (TEIC), a VCM analog, in combination with TAZ/PIPC are scarce. In this study, we investigated the influence of TEIC and TAZ/PIPC combination therapy on renal function.
We conducted a retrospective study to compare the TEIC and TAZ/PIPC combination therapy (TT) group with the TEIC and meropenem combination therapy (TM) group. We obtained data of patients treated between January 2018 and January 2022 and investigated changes in renal function.
We extracted 75 and 95 patients in the TT and TM groups, respectively. The incidence rates of AKI in the TT and TM groups were 16.0% (12 patients) and 14.7% (14 patients), respectively. Propensity score analysis using the inverse probability of treatment weighting method was conducted to adjust for background factors. The comparison revealed no significant differences (P = 0.56) among the treatment groups. In addition, there was no difference in the number of days to AKI onset. A multivariate analysis was also conducted to explore the risk factors associated with the development of AKI. Serum albumin level, quick sequential organ failure assessment score, duration of concomitant therapy, administration of loop diuretics, and administration of vasopressors were identified as the risk factors.
The results indicated that the incidence of AKI did not increase in the TT group compared with the TM group. Thus, TEIC, as an anti-methicillin-resistant Staphylococcus aureus agent, may be safer for kidney function than vancomycin when used in combination with TAZ/PIPC.

Key words：teicoplanin, tazobactam/piperacillin, meropenem, combination therapy, acute kidney injury

e-mail: matsuya-shota＠kansaih.johas.go.jp

Received: April 19, 2022
Accepted: September 22, 2022

38 (1)：16─21,2023